Clinuvel Pharmaceuticals (ASX:CUV) said it will repurchase a maximum of 1.5 million ordinary fully-paid shares as part of an on-market buyback, according to a Thursday Australian bourse filing.
The repurchases are expected to start on April 10 and will run for 12 months, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.